A Phase I Cohort-Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Influenza A H5N8 vaccine-Seqiris (Primary) ; AS03A; MF 59
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- 05 Jan 2023 Results published in the Clinical Infectious Diseases
- 24 Oct 2019 Status changed from active, no longer recruiting to completed.
- 28 Feb 2019 Planned End Date changed from 30 Jan 2019 to 30 Jan 2020.